Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 20/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 5/20 | 1.00 |
| ▸ | ALOX5 | P09917 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1193621 | 0.95 | ALOX5AP (0.91) | ALOX5APCYP2C9ALOX5CYP3A4CYP2D6 | |
| SCHEMBL9305628 | 0.93 | ALOX5AP (0.87) | ALOX5APCYP2C9ALOX5CYP3A4CYP2D6 | |
| SCHEMBL169407 | 0.92 | ALOX5AP (1.00) | ALOX5APCYP2C9ALOX5CYP3A4CYP2D6 | |
| SCHEMBL166648 | 0.92 | ALOX5AP (0.88) | ALOX5APCYP2C9ALOX5CYP3A4CYP2D6 | |
| SCHEMBL169077 | 0.90 | ALOX5AP (0.82) | ALOX5APCYP2C9ALOX5CYP3A4CYP2D6 | |
| SCHEMBL25967880 | 0.90 | ALOX5AP (0.82) | ALOX5APCYP2C9ALOX5CYP3A4CYP2D6 | |
| SCHEMBL9173601 | 0.90 | ALOX5AP (1.00) | ALOX5APCYP2C9ALOX5CYP3A4CYP2D6 | |
| SCHEMBL9305688 | 0.90 | ALOX5AP (1.00) | ALOX5APCYP2C9ALOX5CYP3A4CYP2D6 | |
| SCHEMBL169228 | 0.90 | ALOX5AP (1.00) | ALOX5APCYP2C9ALOX5CYP3A4CYP2D6 | |
| SCHEMBL1722957 | 0.90 | ALOX5AP (0.89) | ALOX5APCYP2C9ALOX5CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718614-B2 | Compounds and methods for treatment of hedgehog pathway associated conditions | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2023-08-08 | — | — | US | disclosed |
| US-20210214353-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SUZHOU MEDNES PHARMA TECH CO., LTD. (CN) | 2021-07-15 | — | — | US | disclosed |
| US-5288743-A | Lipoxygenase inhibitors | ABBOTT LABORATORIES (US) | 1994-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718614-B2 | Compounds and methods for treatment of hedgehog pathway associated conditions | SHH, GLI1, SMO | ALOX5AP 3783/4885CYP2C9 3780/4885ALOX5 1983/4885 |
| US-20210214353-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF HEDGEHOG PATHWAY ASSOCIATED CONDITIONS | SHH, GLI1, SMO | ALOX5AP 3783/4885CYP2C9 3780/4885ALOX5 1983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.